Carlos Fernandez Teruel
Overview
Explore the profile of Carlos Fernandez Teruel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
95
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shore N, Mellado B, Shah S, Hauke R, Costin D, Adra N, et al.
Clin Genitourin Cancer
. 2022 Dec;
21(2):278-285.
PMID: 36572571
Background: Although androgen receptor-targeted agents prolong the lives of patients with metastatic prostate cancer, patients develop therapy resistance and most ultimately succumb to the disease. The PI3K/AKT/PTEN pathway has been...
2.
Jimeno A, Sharma M, Szyldergemajn S, Gore L, Geary D, Diamond J, et al.
Invest New Drugs
. 2017 Jan;
35(4):471-477.
PMID: 28105566
Background Lurbinectedin administered as a 1-h intravenous infusion every 3 weeks induces neutropenia, with the nadir usually occurring during the second week. This phase I study evaluated an alternative lurbinectedin...
3.
Paz-Ares L, Forster M, Boni V, Szyldergemajn S, Corral J, Turnbull S, et al.
Invest New Drugs
. 2016 Nov;
35(2):198-206.
PMID: 27873130
Background To determine the recommended dose (RD) of a combination of PM01183 and gemcitabine in patients with advanced solid tumors. Methods Forty-five patients received escalating doses of PM01183/gemcitabine on Days...
4.
Myat Moe M, Teruel C, Soto-Matos A
Chemotherapy
. 2014 Aug;
59(6):458-60.
PMID: 25171649
Background: We wanted to evaluate the impact of peritoneal dialysis on trabectedin therapy in terms of side effects, response and levels in the blood and dialysate of a patient on...
5.
Elez M, Tabernero J, Geary D, Macarulla T, Kang S, Kahatt C, et al.
Clin Cancer Res
. 2014 Feb;
20(8):2205-14.
PMID: 24563480
Purpose: Lurbinectedin (PM01183) binds covalently to DNA and has broad activity against tumor cell lines. This first-in-human phase I study evaluated dose-limiting toxicities (DLT) and defined a phase II recommended...
6.
Gonzalez-Sales M, Valenzuela B, Perez-Ruixo C, Teruel C, Miguel-Lillo B, Soto-Matos A, et al.
Clin Pharmacokinet
. 2012 Oct;
51(11):751-64.
PMID: 23055348
Background And Objective: PM00104 (Zalypsis(®)) is a novel marine-derived compound that has shown antineoplastic activity against a number of human tumour cell lines. Myelosuppression was found to be a PM00104...
7.
Perez-Ruixo C, Valenzuela B, Teruel C, Gonzalez-Sales M, Miguel-Lillo B, Soto-Matos A, et al.
Cancer Chemother Pharmacol
. 2011 May;
69(1):15-24.
PMID: 21590449
Objective: The aim of this study was to characterize the population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients. Methods: A total of 135 patients included in four phase I clinical...
8.
Cabrera Perez M, Garcia A, Teruel C, Alvarez I, Bermejo Sanz M
Eur J Pharm Biopharm
. 2003 Sep;
56(2):197-206.
PMID: 12957633
The topological-substructural molecular design approach was used to estimate the human bioavailability (F) and the minimum inhibitory concentration (MIC90) against Streptococcus pneumoniae from a data set of 17 and 19...
9.
Cabrera Perez M, Diaz H, Teruel C, Bermejo Sanz M
Eur J Pharm Biopharm
. 2002 Apr;
53(3):317-25.
PMID: 11976020
The ToSS MoDe approach is used to estimate the n-octanol/buffer partition coefficient, the apparent intestinal absorption rate constant and intestinal permeability from a 6-fluoroquinolone data set. Improved in silico methods...